Inmune Bio Inc. CEO Raymond Tesi told BioWorld his firm is taking an “oncology-style” approach to Alzheimer’s disease (AD) as the firm tests next-generation tumor necrosis factor (TNF) inhibitor XPro-1595 against neuroinflammation. It’s working. Shares of the La Jolla-based firm (NASDAQ:INMB) closed at $15.75, up $6.90, or 78%, after the company reported interim findings from a phase Ib experiment that […]

Inmune Bio (INMB) stock skyrocketed to a record high Tuesday after the biotech company unveiled promising results for its Alzheimer’s treatment. Researchers tested the Alzheimer’s treatment in six patients over 12 weeks. At a lower dose, patients showed a 1.7% increase in brain inflammation. Patients who received a higher dose showed a 2.3% decrease. That compares with […]

The Business Of Biotech “Summer Executive Sessions” kick off with a candid conversation with Athersys CFO Ivor Macleod, who brings years of finance leadership at Roche, Merck, and other big pharmas to Athersys as the company readies its lead candidate for life beyond clinical trials. Join us for a discussion on how Macleod is applying […]